Journal Information
Journal ID (publisher-id): BM
Journal ID (nlm-ta): Biochem Med (Zagreb)
Title: Biochemia Medica
Abbreviated Title: Biochem. Med. (Zagreb)
ISSN (print): 1330-0962
ISSN (electronic): 1846-7482
Publisher: Croatian Society of Medical Biochemistry and Laboratory Medicine
Article Information
Copyright statement: ©Croatian Society of Medical Biochemistry and Laboratory Medicine.
Copyright: 2022, Croatian Society of Medical Biochemistry
License (open-access):
This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Date received: 02 June 2022
Date accepted: 20 September 2022
Publication date (electronic): 15 December 2022
Publication date (print): 15 February 2023
Volume: 33
Issue: 1
Electronic Location Identifier: 010701
Publisher ID: bm-33-1-010701
DOI: 10.11613/BM.2023.010701
Association of serum ADMA, SDMA and L-NMMA concentrations with disease progression in COVID-19 patients
Adnan Haşimi[1]
Özlem Doğan[2]
Ceyhan Ceran Serdar[3]
[1] Department of Medical Biochemistry, Faculty of Medicine, Medipol University, Istanbul, Turkey
[2] Department of Biochemistry, Ankara University School of Medicine, Ankara, Turkey
[3] Medical Biology and Genetics, Faculty of Medicine, Ankara Medipol University, Ankara, Turkey
[4] Department of Medical Biochemistry, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
Author notes:
[*] Corresponding author: muhittin.serdar@acibadem.edu.tr
Introduction
This study determines and compares the concentrations of arginine and methylated arginine products ((asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), n-monomethyl-1-arginine (L-NMMA) and homoarginine (HA)) for assessment of their association with disease severity in serum samples of COVID-19 patients.
Materials and methods
Serum arginine and methylated arginine products of 57 mild-moderate and 29 severe (N = 86) COVID-19 patients and 21 controls were determined by tandem mass spectrometry. Moreover, the concentrations of some of the routine clinical laboratory parameters -neutrophil lymphocyte ratio (NLR), C-reactive protein, ferritin, D-dimer, and fibrinogen measured during COVID-19 follow-up were also taken into consideration and compared with the concentrations of arginine and methylated arginine products.
Results
Serum ADMA, SDMA and L-NMMA were found to be significantly higher in severe COVID-19 patients, than in both mild-moderate patients and the control group (P < 0.001 for each). In addition, multiple logistic regression analysis indicated L-NMMA (cut-off =120 nmol/L OR = 34, 95% confidence interval (CI) = 3.5-302.0, P= 0.002), CRP (cut-off = 32 mg/L, OR = 37, 95% CI = 4.8-287.0, P < 0.001), and NLR (cut-off = 7, OR = 22, 95% CI = 1.4-335.0, P = 0.020) as independent risk factors for identification of severe patients.
Keywords: SARS-CoV-2; asymmetric dimethylarginine (ADMA); N-monomethyl-1 -arginine (L-NMMA); prognosis
